期刊
ANTIVIRAL RESEARCH
卷 100, 期 2, 页码 392-398出版社
ELSEVIER
DOI: 10.1016/j.antiviral.2013.08.025
关键词
Polyoxometalate; Antiviral; Hepatitis C virus; Virucidal
资金
- National Science and Technology Major Project [2012ZX10002007-003]
- National Natural Science Foundation of China [30870127, 81072337]
- CAS/SAFEA International Partnership Program for Creative Research Teams, S & T Development Project Foundation of Jilin Province [201101057]
- China Postdoctoral Science Foundation [20100481064, 2012T50307]
Hepatitis C virus (HCV) infects about 2% of the world population. The standard treatment of chronic HCV infection is still discontented because of the low sustained virological response rate. The development of new HCV antivirals is a healthcare imperative. We explored the potentials of polyoxometalates to inhibit HCV infection using newly developed HCVcc cell culture system. We found one polyoxometalate compound (named POM-12) can inhibit HCV infection at the nanomolar range while displayed little cytotoxicity. We showed that POM-12 inhibited pseudotyped HCV infection but had no effect on HCV RNA replication. Furthermore, we showed that POM-12 was virucidal and can disrupt HCV particles. Finally we demonstrated that POM-12 had no effect on the vesicular stomatitis virus infection while had weak inhibitory activity against the influenza virus infection. In conclusion, we identified a potent anti-HCV compound which may provide an attractive drug candidate to cure HCV infection. (C) 2013 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据